Clinical Trial Update: Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating subcutaneous blinatumomab in adults with CD19-positive mixed phenotype acute leukemia (MPAL). The study is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mixed Phenotype Acute Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)

Snippet

Sponsor: West Virginia University | Conditions: CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL) | Phase 2 | Status: RECRUITING